COPD Trial, Recruiting NCT07245576 Sponsor: AstraZeneca Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT07245576
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the suspected asthma group:

  • People aged 18 or older (or the legal age of consent in the country where the study is taking place) who have not yet been formally diagnosed with asthma
  • People experiencing symptoms such as wheezing, coughing, chest tightness, or shortness of breath, without a confirmed asthma diagnosis

For the suspected COPD group:

  • People aged 40 or older who have not yet been formally diagnosed with COPD
  • People experiencing symptoms such as breathlessness, a long-lasting cough, or regularly coughing up mucus, without a confirmed COPD diagnosis

Who may not be able to join:

  • People who have already been diagnosed with COPD or asthma
  • People who have used inhaled corticosteroid (steroid) medicines in the past 6 months, or steroid tablets/liquids taken by mouth in the past 3 months
  • People with other conditions that affect how the lungs work, such as lung cancer, pneumonia, active tuberculosis, pulmonary embolism, or certain scarring lung diseases
  • People who have recently had surgery affecting the lungs or chest, such as chest-opening surgery, surgery for a collapsed lung, or chest drainage procedures
  • People for whom breathing tests (spirometry or oscillometry) are not medically appropriate, or who have an allergy to bronchodilator medicines (medicines that open the airways)
  • People who are currently pregnant or breastfeeding
  • People whom the trial doctor considers unlikely to be able to follow the study's procedures and requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
26 December 2025
Est. completion
30 April 2027

Where this trial is recruiting

🇦🇷 Argentina 🇪🇬 Egypt 🇲🇽 Mexico 🇸🇦 Saudi Arabia 🇹🇼 Taiwan 🇦🇪 United Arab Emirates 🇻🇳 Vietnam

Primary endpoints

Accuracy of primary care asthma/COPD diagnosis using oscillometry (ALDS: R5, R20, R5-R20, X5, Ax) plus FeNO ≥50 ppb (Fenom PRO®/ALDS Pro) vs specialist gold standard; metrics: Cohen's kappa, agreement, sensitivity, specificity in overall, asthma, COPD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov